Rockville, MD, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Polycystic ovarian syndrome is a disorder in which several tiny cysts (fluid-filled sacs) grow in the ovaries. The market is projected to expand steadily as more females around the world become aware of the risks associated with the condition. The global polycystic ovary syndrome (PCOS) treatment market is estimated to reach a valuation of US$ 4.33 billion in 2024 and further expand at a CAGR of 4.7% from 2024 to 2034.
One of the most common signs of PCOS is an irregular menstrual cycle. Women often opt for testing for PCOS upon noticing this symptom. Women are increasingly mindful of their health and actively endeavor to improve it and monitor for health concerns. All of these factors are boosting the adoption of PCOS treatment.
Treatment providers in the market are striving to gain a deeper understanding of women's reproductive functions to enhance their treatment features, attracting more women to choose their treatment options. This is contributing to the expansion of the polycystic ovary syndrome treatment market size.
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10043
Key Takeaways from Market Study
- The global polycystic ovary syndrome treatment market is expected to reach US$ 6.84 billion by 2034-end.
- The North American market is forecasted to expand at a CAGR of 4.3% till 2034.
- Oral contraceptives are estimated to account for 30.4% share of the market by 2024.
- Through 2034, the East Asia market is projected to expand at 6% CAGR.
- The Japanese market is projected to expand at a CAGR of 5.5% from 2024 to 2034.
- The PCOS market in Mexico is forecasted to reach a valuation of US$ 136 million by 2034-end.
“Rise in the prevalence of polycystic ovary syndrome worldwide prompts the development of effective treatment options. Increasing awareness and proactive measures are crucial for managing PCOS to improve women's health worldwide,” says a Fact.MR analyst.
Leading Players Driving Innovation in the Polycystic Ovary Syndrome (PCOS) Treatment Market:
Key industry participants like Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Crinetics Pharmaceuticals, AstraZeneca Plc, Aphena Pharma Solutions Tennessee, Inc., Lupin Pharmaceuticals, Sun Pharmaceutical Industries Ltd. etc. are driving the polycystic ovary syndrome (PCOS) treatment industry.
United States and China Profitable Markets for PCOS Treatment Providers:
Expansion of healthcare infrastructure in the United States, coupled with increased disposable income, has contributed to the adoption of insulin-sensitizing agents. Awareness campaigns by United States government entities have contributed to market growth in the nation. The market shows promising signs as proactive measures by the government become more prominent.
Prevalence of PCOS among women in China has increased significantly over the past decade. A significant number of reproductive-aged women in China are affected by PCOS. Therefore, national regulations and recommendations should be updated based on recent research. Consequently, the Chinese market holds lucrative opportunities for PCOS treatment providers.
Polycystic Ovary Syndrome (PCOS) Treatment Industry News:
- In June 2022, Bayer took a significant step by inaugurating its new Research and Innovation Center at Kendall Square in the United States. This move reinforces Bayer’s presence in one of the world’s most dynamic hubs for pharmaceutical research and development.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10043
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the polycystic ovary syndrome treatment market for 2018 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on drug class (oral contraceptives, insulin-sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs, diuretics) and distribution channel (hospital pharmacies, drug stores/OTC, e-Commerce, clinics), across six major regions of the world (North America, Latin America, Europe, East Asia, South Asia & Oceania, and MEA).
Check out More Related Studies Published by Fact.MR Research:
Contraceptives market size is set to increase from a value of US$ 33 billion to US$ 62 billion by the end of 2033.
Pregnancy point of care testing market is valued at US$ 1.5 billion in 2023 and is forecasted to secure US$ 2.33 billion in revenue by 2033-end.
Women's health rehabilitation products market is predicted to increase from its current valuation of US$ 3.22 billion and reach US$ 5.77 billion by the end of 2033.
Insulin delivery devices market size have reached at US$ 16.8 Billion in 2023, and is expected to secure a valuation of US$ 33.1 Billion by 2033-end, with a growing compound annual growth rate (CAGR) of 7% during the forecast period from 2023 to 2033.
Insulin patch pumps market size was valued at US$ 840 Million in 2022 and is expected to accumulate a market value of US$ 932.40 Million by registering a CAGR of 11% in the forecast period 2022-2032.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
